Biopharmaceutical News and Research

RSS

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011

KAEL-GemVax wins European telomerase patent challenge

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that the recent ruling by the European Patent Office dismissing appeals relating to Geron Corporation's European telomerase patent confirms KAEL-GemVax's patent position on lead product GV-1001, an anti-telomerase vaccine, currently completing the TeloVac Phase III trial for pancreatic cancer.

9 May 2011

caprotec bioanalytics closes Series B financing for EUR 5 million

caprotec bioanalytics GmbH, a privately held biopharmaceutical company offering the proprietary Capture Compound Mass Spectrometry platform technology for the analysis of small molecule – protein interactions, today announced a second closing of EUR 1 million to its Series B financing, increasing total equity for the round to EUR 5 million.

9 May 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

Caisse des Dépôts, sanofi-aventis sign memorandum of understanding for Caisse des Dépôts Investment in Biocitech life science technology park

sanofi-aventis and France’s Caisse des Dépôts announce today that the Caisse des Depots will acquire an interest in the Paris-based Biocitech life sciences technology park. Biocitech plays a key role in the development of the biotechnology industry in the department of Seine-Saint-Denis and the Greater Paris region.

7 May 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

7 May 2011

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.

6 May 2011

CytRx reports $6.3 million net loss for first quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

5 May 2011

Over 1000 patients enrolled in world's largest ever pancreatic cancer vaccine trial

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that it had been officially notified by the independent Data Monitoring Committee that over 1000 patients have been enrolled in the TeloVac Study, making it the world's largest ever pancreatic cancer vaccine trial.

5 May 2011

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.

5 May 2011

Yale, Debiopharm partner to develop and commercialize Debio 1036 for inflammatory diseases

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.

4 May 2011

Nile Therapeutics initiates cenderitide Phase I trial in heart failure

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced dosing of the first patient in a Phase I clinical trial investigating the use of subcutaneous cenderitide.

3 May 2011

Ipsen first quarter sales increase 6.1% to €285.8 million

Ipsen reported today its sales for the first quarter 2011.

3 May 2011

Oragenics announces availability of oral care probiotics for children and adults

Florida-based biopharmaceutical company Oragenics, Inc. has announced that its oral care probiotics for children and adults will be available in Australia and New Zealand through an exclusive agreement with Australian Pharmaceutical Industries, owner of the Priceline pharmacy retail chain, and one of the leading service providers to the pharmacy industry.

3 May 2011

Sanofi Pasteur, EnGen Bio and Dyadic Nederland sign research deal for vaccine development

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the biopharmaceutical, biofuels and industrial enzyme industries, announced today that its research and development subsidiary, Dyadic Nederland B.V., has entered into a research agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and EnGen Bio, Inc.

3 May 2011

Bioniche Life Sciences opens new livestock vaccine manufacturing facility

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today officially opened its new Animal Health and Food Safety Vaccine Manufacturing Centre at its corporate headquarters in Belleville, Ontario, Canada.

30 Apr 2011

Winner of MDEA Lifetime Achievement Award announced

UBM Canon's Medical Design Excellence Awards has announced the winner of the Medical Design Excellence Awards Lifetime Achievement Award. This award honors an individual whose contributions during a long career have had a demonstrable impact on technological, business, and cultural advancements in medical devices.

30 Apr 2011

Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease, today announced its results for the first quarter ended March 31, 2011.

30 Apr 2011

NeurogesX first quarter revenue is $3.2 million for 2011

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for its first quarter ended March 31, 2011.

30 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Biopharmaceutical News and Research

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

KAEL-GemVax wins European telomerase patent challenge

caprotec bioanalytics closes Series B financing for EUR 5 million

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Caisse des Dépôts, sanofi-aventis sign memorandum of understanding for Caisse des Dépôts Investment in Biocitech life science technology park

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

CytRx reports $6.3 million net loss for first quarter 2011

Over 1000 patients enrolled in world's largest ever pancreatic cancer vaccine trial

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Yale, Debiopharm partner to develop and commercialize Debio 1036 for inflammatory diseases

Nile Therapeutics initiates cenderitide Phase I trial in heart failure

Ipsen first quarter sales increase 6.1% to €285.8 million

Oragenics announces availability of oral care probiotics for children and adults

Sanofi Pasteur, EnGen Bio and Dyadic Nederland sign research deal for vaccine development

Bioniche Life Sciences opens new livestock vaccine manufacturing facility

Winner of MDEA Lifetime Achievement Award announced

Keryx Biopharmaceuticals reports net loss of $6.4 million for first quarter 2011

NeurogesX first quarter revenue is $3.2 million for 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

Biotechnology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News